anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A dehydrated liposome formulation containing retinol palmitate and astaxanthin is provided to suppress deterioration of retinol palmitate and astaxanthin and ensure high reproducibility. CONSTITUTION: A dehydrated liposome formulation contains retinol palmitate, astaxanthin and ascorbic acid and/or its salt. The formulation contains 1-10 weight parts of axtaxanthin and 40-200 weight parts of ascorbic acid based on retinol plamitate. The formulation additionally contains sucrose. The formulation is produced by freeze-drying or spray-drying ascorbic acid solution in which liposome is dispersed. The skin external formulation contains the dehydrated liposome formulation as a first agent and aqueous formulation as a second agent.
1. Technical Result Increase in therapeutic effect and composition purity.         2. Essence A composition comprises phagolyzates Salmonellae paratiphy A, Salmonellae Paratiphy B, Salmonellae choleraesuis, Salmonellae enteritidis, Salmonellae typhimurium, Salmonellae oranienburg, Salmonellae dublin, Salmonellae newlands, Salmonellae newport, Salmonellae anatum, Salmonellae heidelberg, and Salmonellae infantis and pharmaceutically acceptable auxiliary.         The medicament comprises placed in the capsule said composition and pharmaceutically acceptable filler. To obtain the composition the microbes are cultured on the nutrient medium and infected by the suitable bacteriophages. A method comprises microfiltration, ultrafiltration of the received phagolizate, the repeated microfiltration or concentration, mixing of the auxiliary and lyophilization.         3. Field of Application Medicine.
Participants in Appendix A will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or the modafinil-matched control. If modafinil is contraindicated for any reason, participants will be assessed for their ability to take solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or the solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks.
This effervescent oral table in a sealed container contains the components (A) to (C) indicated below. The ratio (HB)/(HA) of the number of moles of acid groups of the component (B) to the number of moles of acid groups of the component (A) when the component (B) comprises only citric acid or a salt thereof or comprises only ascorbic acid or a salt thereof is 0.1-4.0, and said ratio is 0.05-5.5 when the component (B) comprises a combination of citric acid or a salt thereof and ascorbic acid or a salt thereof. In addition, the ratio [(HA)+(HB)]/(C) of the total number of moles of acid groups of the components (A) and (B) to the number of moles of the component (C) is 0.7-1.35.　Component (A): tartaric acid or a salt thereof, 0.1-22 mass%. Component (B): citric acid, ascorbic acid, or a salt thereof. Component (C): a carbonate, 14-30 mass%.
Provided herein are polymer-stabilized CaP nanoparticle formulations and related methods of manufacture. In certain embodiments, the methods reliably and selectively form nanoparticles with homogenous size, charge, and morphology. The CaP nanoparticles include calcium ions and phosphate ions with an ionic polymer, thereby forming stable hybrid nanoparticles. The CaP nanoparticle formulations include powders, suspensions and injectable pastes. According to various embodiments, the polymer-stabilized CaP nanoparticles may be polycation-stabilized (CaP/polymer(+) nanoparticles) or polyanion-stabilized (CaP/polymer(-) nanoparticles). The CaP/polymer nanoparticles can be freeze-dried and stored for months with no loss of properties or changes to their morphology.
PURPOSE:To obtain a formed body with small deviation of weight per unit length by a method wherein gelatinous high polymer molecule substance consisting of water and high polymer molecule substance is poured into a casting mold, frozen, thereafter, taken out under frozen condition and dried. CONSTITUTION:The mixture of one kind or two kinds or more of collagen or the like is prepared so as to have proper concentration and viscosity, subsequently, is poured into a proper casting mold or a tube having a proper inner diameter, for example, and is frozed as it is. After freezing sufficiently, a molded body under frozen condition is taken out of the casting mold and is dried under a normal temperature. Such a time and temperature of freezing is enough that the molded product has a hardness with which the formed product is not collapsed upon mold releasing. On the other hand, drying conditions are arbitrary and either one of suction drying, natural drying or freezing drying may be employed. The molded product, obtained by this method, has no variability in the configuration thereof substantially and, accordingly, the deviation in weight per unit length is very small. When the gelatinous high polymer molecule substance is mixed with medicals, medicines for medical use can be obtained.
Background Chronic conditions may limit older peoples' social engagement and wellbeing. Reduced social connections can result in loneliness and social isolation. This study aimed to explore the experience of social connection in older people living with chronic conditions, and the factors influencing their social participation. Methods A purposive sample of 19 community-dwelling older Australians (mean age 75.5years) with one or more chronic conditions participated in a qualitative descriptive study. Semi-structured interviews explored participants' perceptions of their social connections and the potential impact of their chronic conditions. Views about the role of general practice in supporting older persons' wellbeing were discussed. Data were analysed inductively using thematic analysis. Results Five themes were identified: (1) the experience of loneliness, (2) managing diminishing social contacts, (3) living with chronic conditions, (4) barriers to social connection, and (5) facilitators of social connection. Participants felt that ageing with chronic conditions contributed to loss of function and independence, which limited social connections, and increased loneliness and social isolation. Barriers to social connections included issues with mobility, transport and forming new networks. Families were a primary support, with continued community engagement and general practice support crucial to staying well and socially connected. Conclusions Understanding older peoples' experiences, and the barriers and facilitators of social connections can guide clinicians' interventions. General practice is a promising intervention point because of its high use by those with chronic conditions to stay well. General practice nurses are well-placed to collaboratively address the barriers older people face in maintaining social connections.
All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the "on" dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform.
Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
The invention provides a traditional Chinese medicine composition for treating cough. The traditional Chinese medicine composition comprises the following raw materials: momordica grosvenori, houttuynia cordata, lalang grass rhizome, perilla stem, the root bark of white mulberry, lily, mother chrysanthemum, isatis root and liquorice. The invention further provides a method for applying the traditional Chinese medicine composition. The method comprises the following steps: taking various traditional Chinese medicine raw materials according to the weight ratio, adding the materials into a decocting container, adding 1.5-3 times of water according to the total weight ratio of the medicinal materials, boiling by using big fire, decocting by using slow fire, stopping heating when the decoction is only 1/3-1/2 of the added water, pouring out the decoction, containing the decoction in a container, and warmly taking the medicine for several times. The traditional Chinese medicine composition disclosed by the invention has the advantages that various raw medicinal materials and ratios thereof are selected under the theory of traditional Chinese medicine and clinical experience guidance, the synergetic or resistive effects of the materials are utilized, the curative effect is improved, the treatment effect is obvious, and the traditional Chinese medicine composition is short in course of treatment and low in cost, does not have any toxic or side effect and treats both symptoms and root causes. The traditional Chinese medicine composition has the effects of straightening the body resistance, dredging collaterals and dispelling cold, promoting blood circulation to remove blood stasis, removing stasis and moistening lung, relieving cough and reducing sputum, detoxifying and relieving pain and resolving hard lump.
The present invention discloses a kind of H5N1 subtype bird flu virus gene engineering subunit vaccine and its preparation process. The vaccine of the present invention consists of: protein obtained through expressing the gene sequence of SEQ ID No. 1 in insect/baculovirus expression system, protein obtained through expressing the gene sequence of SEQ ID No. 2 in prokaryotic expression system, and immunological adjuvant. After being used in immunizing chicken, the vaccine can excite excellent protecting immune reaction, and has no danger of live virus, no gene recombination, toxicity re-strengthening and other faults. The immunized and the naturally infected may be distinguished, and this results in no interference on epidemiological investigation and no environment and ecological safety problem.
<P>PROBLEM TO BE SOLVED: To read medical image data with unmatched patient information without correcting the patient information.  <P>SOLUTION: A patient archiving and communication system (PACS) obtains a digital imaging and communication in medicine (DICOM) image from a modality. The PACS determines the matching between the patient information included in supplementary information included in the DICOM image and the patient information included in the supplementary information of the pre-managed DICOM image data. If the result of determination is "matched", the PACS updates a patient information master table T1, etc. If the result of determination is "unmatched", the PACS updates a patient information unmatched table T2, etc. Then, the PACS manages the otained DICOM image data together with the pre-managed DICOM image data.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:A novel skin cosmetic forming a protecting film of stachyose, providing the skin with proper moisture and liveliness, exhibiting improved health promoting, beautifying and protecting effect on the skin, obtained by blending a water-soluble base of skin cosmetic with stachyose. CONSTITUTION:An aqueous base of skin cosmetic is blended with preferably 0.05-10wt% based on total amounts of components treated of stachyose, an oligosaccharide obtained by purifying a water-soluble fraction of the root of Rehmannia glutinosa purpurea Lib. var. purpurea Makino or a plant belonging to the same genus, showing a white powdery state, being easily water-soluble, to give a skin cosmetic. It can be used as a lotion, cream, milky lotion, or pack. This stachyose has improved properties such as water retention, moisture absorption, inhibitory action on endermic water evaporation, film-forming action, safety, etc.
A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
Participants will receive intramuscular injection of fulvestrant 2 mg/kg or 4 mg/kg (First 10 participants will be dosed at 2 mg/kg then increased to 4 mg/kg. All subsequent participants will be dosed at 4 mg/kg) into the buttock or thigh monthly for 12 months or until the participant demonstrates lack of efficacy based upon one or more of the primary endpoints or experiences a serious drug-related toxicity requiring treatment discontinuation.
PURPOSE:To provide an antitumor agent containing a specific compound including known substance having sufficiently ascertained safety, exhibiting the effect to decrease the number of tumor cells, improve the life prolongation rate and suppress the proliferation of the tumor cell, and effective to animal or human tumor. CONSTITUTION:The objective agent contains the compound of formula I (R is H, CH3 or OCH3) or its salt, preferably 6-chloro-5-cyclohexyl-1- indanecarboxylic acid of formula II (R is H) as an active component. The active component is used singly or as a mixture with pharmacologically permissible carrier or adjuvant, and administered orally in the form of powder, tablet, capsule, etc. including sublingual administration, or parenterally in the form of injection in ampule, etc., suppository, ointment, etc. by injection, rectal infusion, etc. or dermal application. The content of the active component in the medicinal drug is 0.1-100wt%, and the component is administered at a dose of 0.1-1,000mg/kg daily for human optionally in 2-4 divided doses.
PURPOSE: A whitening toothpaste composition using titanium dioxide fine powders is provided. The adhesion of the titanium dioxide fine powders on the surface of teeth exhibits teeth whitening effects. The formulation and package of the final product of the composition is provided with the shape of a conventional tubed ointment(paste phase). CONSTITUTION: The whitening toothpaste composition contains 0.1 to 10.0% by weight of titanium dioxide fine powders having a particle size of 10 to 200nm as a whitening agent. It also contains 0.05 to 0.15% by weight of fluoride and 5 to 50% by weight of a polishing agent, based on the total weight of the composition. The polishing agents are one or more selected from the group consisting of precipitated silica, silica gel, zirconium silicate, dicalcium phosphate dihydrate, dicalcium phosphate anhydrous, hydrous alumina, light calcium carbonate, heavy calcium carbonate, potassium pyrophosphate, insoluble metaphosphate and aluminium silicate.
Only physicians experienced in management of systemic immunosuppressive therapy for the indicated disease should prescribe Gengraf® Oral Solution (cyclosporine oral solution, USP [MODIFIED]). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Gengraf®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

Gengraf®, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Gengraf® may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.

Gengraf® Oral Solution (cyclosporine oral solution, USP [MODIFIED]) has increased bioavailability in comparison to Sandimmune® Oral Solution (cyclosporine oral solution, USP). Gengraf® and Sandimmune® are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Gengraf® than with Sandimmune®. If a patient who is receiving exceptionally high doses of Sandimmune® is converted to Gengraf®, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Gengraf® to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed (see DOSAGE AND ADMINISTRATION).
Patients receive ibrutinib 420 mg PO QD on days 1-21 and brentuximab vedotin 1.8 mg/kg IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Acute hypobaric hypoxia-induced brain injury has been a challenge in the health management of mountaineers; therefore, new neuroprotective agents are urgently required. Meldonium, a well-known cardioprotective drug, has been reported to have neuroprotective effects. However, the relevant mechanisms have not been elucidated. We hypothesized that meldonium may play a potentially novel role in hypobaric hypoxia cerebral injury.
METHODS: We initially evaluated the neuroprotection efficacy of meldonium against acute hypoxia in mice and primary hippocampal neurons. The potential molecular targets of meldonium were screened using drug-target binding Huprot™ microarray chip and mass spectrometry analyses after which they were validated with surface plasmon resonance (SPR), molecular docking, and pull-down assay. The functional effects of such binding were explored through gene knockdown and overexpression.
RESULTS: The study clearly shows that pretreatment with meldonium rapidly attenuates neuronal pathological damage, cerebral blood flow changes, and mitochondrial damage and its cascade response to oxidative stress injury, thereby improving survival rates in mice brain and primary hippocampal neurons, revealing the remarkable pharmacological efficacy of meldonium in acute high-altitude brain injury. On the one hand, we confirmed that meldonium directly interacts with phosphoglycerate kinase 1 (PGK1) to promote its activity, which improved glycolysis and pyruvate metabolism to promote ATP production. On the other hand, meldonium also ameliorates mitochondrial damage by PGK1 translocating to mitochondria under acute hypoxia to regulate the activity of TNF receptor-associated protein 1 (TRAP1) molecular chaperones.
CONCLUSION: These results further explain the mechanism of meldonium as an energy optimizer and provide a strategy for preventing acute hypobaric hypoxia brain injury at high altitudes.
The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study is an interdisciplinary, community-based, prospective longitudinal epidemiologic study examining the influences of race and socioeconomic status (SES) on the development of age-related health disparities among socioeconomically diverse African Americans and whites in Baltimore. This study investigates whether health disparities develop or persist due to differences in SES, differences in race, or their interaction. HANDLS is unique because it assesses physical parameters as well as evaluating genetic, biologic, demographic, and psychosocial parameters of African American and white participants over a wide range of socioeconomic statuses, longitudinally. HANDLS also employs novel research tools, mobile medical research vehicles, in hopes of improving participation rates and retention among non-traditional research participants. The domains of the HANDLS study include: nutrition, cognition, biologic biomarkers, body composition and bone quality, physical function and performance, psychology, genomics, neighborhood environment and cardiovascular disease. Utilizing data from these study domains will facilitate an understanding of selected underlying factors of persistent black-white health disparities in overall longevity, cardiovascular disease, and cognitive decline.

HANDLS recruited a fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009 as Wave 1. HANDLS Wave 2 entitled The Association of Personality and Socioeconomic status with Health Status An Interim Follow-up Study began in June 2006 under a separate protocol. It was designed as a follow-up telephone interview approximately 18 months after the initial examination (Wave 1) was complete. Wave 2 provided interim contact with study participants, and important interim information regarding their health. Now completed, waves 3, 4 and 5 were follow-up examinations visits to our mobile Medical Research Vehicles (MRVs). In September 2020, HANDLS initiated wave 6; telephone interviews and limited in-person visits as a COVID-centric protocol. The current protocol outlines Wave 7, the fourth follow-up examination and the participants fifth visit to our mobile Medical Research Vehicles (MRVs). Planned as a follow-up after 3-4 years, Wave 7 consists of health examinations, questionnaires, sensory assessments (visual and olfactory), health literacy assessment, renal function assessments, environmental assessments, and for a sub-set of participants; structural MRIs, a personality inventory and an examination of sleep and cognition under separate protocols. HANDLS will resume in-person examinations with wave 7 in which we will prioritize contacting participants who were not seen in wave 5.
The objective of this study was to investigate the effects and molecular mechanisms of tetrahedral framework nucleic acids-microRNA22 (tFNAs-miR22) on inhibiting pathological retinal neovascularization (RNV) and restoring physiological retinal vessels. A novel DNA nanocomplex (tFNAs-miR22) was synthesised by modifying microRNA-22 (miR22) through attachment onto tetrahedral frame nucleic acids (tFNAs), which possess diverse biological functions. Cell proliferation, wound healing, and tube formation were employed for in vitro assays to investigate the angiogenic function of cells. Oxygen-induced retinopathy (OIR) model was utilised to examine the effects of reducing pathological neovascularization (RNV) and inhibiting vascular occlusion in vivo. In vitro, tFNAs-miR22 demonstrated the ability to penetrate endothelial cells and effectively suppress cell proliferation, tube formation, and migration in a hypoxic environment. In vivo, tFNAs-miR22 exhibited promising results in reducing RNV and promoting the restoration of normal retinal blood vessels in OIR model through modulation of the Wnt pathway. This study provided a theoretical basis for the further understanding of RNV, and highlighted the innovative and potential of tFNAs-miR22 as a therapeutic option for ischemic retinal diseases.